Good morning! I have been in this stock when it was OTC and I'd be lying if I said that I am not extremely disappointed given the Biogen news this morning.

The limited amount of news that gets dripped on us is encouraging but the lack of clarity for the direction of AVXL is heading continues to discourage me especially on days like this. GLTA...

I listened to the presentation and, I hate to say it, but I agree with the McMagyar’s interpretation of the licensing statement.

The comment doesn’t hold any weight but I took notice at that point. Thx.

Poster Presentation Title: THE DUAL REGULATION OF OXIDATIVE STRESS BY SIGMA1 RECEPTORS IN PHYSIOLOGICAL OR PATHOLOGICAL CONDITIONS (Data related to ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41)

""Our new PT reflects $235 for the base biz and $70 for Alzheimer's candidate aducanumab (2H19 data)," the note said.'

Any chance someone could please share the details for the upcoming April shareholder meeting in NYC? Thanks!

Anavex Life Sciences Corp. (AVXL) Receives Buy Rating from Maxim Group
Posted by Jared Coughlin on Nov 29th, 2016 // No Comments

Anavex Life Sciences Corp. logoAnavex Life Sciences Corp. (NASDAQ:AVXL)‘s stock had its “buy” rating restated by research analysts at Maxim Group in a report issued on Tuesday. They presently have a $15.00 target price on the stock. Maxim Group’s price objective would suggest a potential upside of 275.00% from the stock’s previous close.

Separately, FBR & Co reissued an “outperform” rating and set a $10.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday, October 5th.

Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 3.15% during midday trading on Tuesday, hitting $4.00. The company had a trading volume of 1,087,985 shares. Anavex Life Sciences Corp. has a one year low of $2.43 and a one year high of $8.30. The company’s 50 day moving average is $3.23 and its 200-day moving average is $3.99. The company’s market cap is $142.84 million.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark and copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2016/11/29/anavex-life-sciences-corp-avxl-receives-buy-rating-from-maxim-group.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD bought a new position in shares of Anavex Life Sciences Corp. during the third quarter worth approximately $108,000. American International Group Inc. acquired a new stake in Anavex Life Sciences Corp. during the second quarter worth about $115,000. Rhumbline Advisers raised its stake in Anavex Life Sciences Corp. by 13.1% in the third quarter. Rhumbline Advisers now owns 35,476 shares of the company’s stock worth $129,000 after buying an additional 4,100 shares during the period. Nationwide Fund Advisors acquired a new stake in Anavex Life Sciences Corp. during the second quarter worth about $130,000. Finally, Credit Suisse AG raised its stake in Anavex Life Sciences Corp. by 28.6% in the third quarter. Credit Suisse AG now owns 65,937 shares of the company’s stock worth $239,000 after buying an additional 14,660 shares during the period. 12.83% of the stock is currently owned by institutional investors and hedge funds.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

https://www.com-unik.info/2016/11/29/anavex-life-sciences-corp-avxl-receives-buy-rating-from-maxim-group.html

http://www.cbsnews.com/news/60-minutes-preview-alzheimers-disease-colombia-lesley-stahl/

Alzheimer's segment on 60 minutes right now on the east coast. Sorry if this was already mentioned.

This will allow AVXL to speed up the testing phase while minimizing the cost: "Anavex’s 32-patient Alzheimer’s study utilizing KEM® will enable systematic analysis of more data on each patient in the disease group, on par with similar studies of significantly larger size, while providing greater cost and time efficiency. '

Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
http://finance.yahoo.com/news/anavex-life-sciences-ariana-pharma-110000363.html